Innovative treatments for complex diseases
At Delta4, we aim to enhance and transform treatment across a broad range of complex as well as rare diseases by discovering and developing proprietary repositioned/repurposed drug candidates.
The process begins with our revolutionary artificial intelligence-powered platform, Hyper-C. Our robust in-silico platform is the result of a combined 70 man-years of development and leverages 15+ major data stores and databases. Hyper-C harvests and analyzes data in order to discover undetected relationships between drugs and diseases on a compound level. It does this with unparalleled efficiency and speed, providing a precise shortlist of potential matches with a high probability of success.
Once Hyper-C’s library of thousands of proprietary algorithms and artificial intelligence has conducted the bulk of the analysis, reviewing volumes of data and iterating through models – accomplishing what may be impossible for human researchers to perform – it’s time for our exceptional team to get to work.
Where many AI drug discovery platforms operate like a black box making it difficult to explain results, Hyper-C delivers a clear mechanism of action hypothesis and biomarkers for patient stratification in clinical trials, making it easier for our team to interpret and work with the results, make decisions, and satisfy regulatory requirements.
Our team of molecular and computational biologists scrutinize the shortlist of compounds and meticulously examine the data in order to identify and move forward with the option that secures the highest probability of success.
After an exacting in-silico selection process followed by a rigorous examination from our team, the drug candidate is ready for the biological testing phase.
With much excitement, our team begins the testing process offering both the in-vitro and the animal models. We also have access to independent experts across various specialties that can assist with the process or verify results.
Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.
